Barclays PLC Novo Nordisk A S Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Barclays PLC holds 441,619 shares of NVO stock, worth $38.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

441,619

Previous 441,619 -0.0%

Holding current value

$38.6 Million

Previous $52.6 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$119.07 - $145.42 $22.2 Million - $27.1 Million	186,525 Added 73.12%	441,619 $52.6 Million
Q2 2024 Aug 14, 2024	SELL	$122.71 - $146.91 $8.27 Million - $9.9 Million	-67,379 Reduced 20.89%	255,094 $36.4 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $28.3 Million - $37.7 Million	277,306 Added 613.96%	322,473 $41.4 Million
Q4 2023 Feb 15, 2024	BUY	$87.78 - $105.45 $2.41 Million - $2.9 Million	27,473 Added 155.27%	45,167 $4.67 Million
Q3 2023 Nov 07, 2023	BUY	$90.94 - $199.54 $357,030 - $783,394	3,926 Added 28.52%	17,694 $1.61 Million
Q2 2023 Aug 03, 2023	BUY	$155.98 - $172.65 $1.65 Million - $1.83 Million	10,603 Added 335.01%	13,768 $2.23 Million
Q1 2023 May 04, 2023	BUY	$132.34 - $159.14 $21,836 - $26,258	165 Added 5.5%	3,165 $503,000
Q3 2022 Nov 03, 2022	SELL	$95.28 - $116.93 $6.7 Million - $8.23 Million	-70,352 Reduced 95.91%	3,000 $299,000
Q2 2022 Aug 12, 2022	BUY	$103.24 - $121.81 $1.06 Million - $1.24 Million	10,220 Added 16.19%	73,352 $8.17 Million
Q1 2022 May 16, 2022	BUY	$93.1 - $112.54 $2.86 Million - $3.45 Million	30,684 Added 94.56%	63,132 $7.01 Million
Q4 2021 Feb 14, 2022	SELL	$95.88 - $117.08 $487,070 - $594,766	-5,080 Reduced 13.54%	32,448 $3.63 Million
Q3 2021 Nov 09, 2021	BUY	$84.42 - $106.62 $2.74 Million - $3.46 Million	32,431 Added 636.28%	37,528 $3.6 Million
Q2 2021 Aug 13, 2021	SELL	$67.66 - $84.76 $409,140 - $512,543	-6,047 Reduced 54.26%	5,097 $427,000
Q1 2021 May 13, 2021	SELL	$67.06 - $75.82 $1.01 Million - $1.14 Million	-15,000 Reduced 57.37%	11,144 $751,000
Q4 2020 Feb 11, 2021	BUY	$63.89 - $73.8 $1.6 Million - $1.85 Million	25,002 Added 2189.32%	26,144 $1.83 Million
Q3 2020 Nov 12, 2020	SELL	$63.69 - $70.22 $32,036 - $35,320	-503 Reduced 30.58%	1,142 $80,000
Q2 2020 Aug 12, 2020	SELL	$58.54 - $67.94 $1.09 Million - $1.26 Million	-18,567 Reduced 91.86%	1,645 $107,000
Q1 2020 May 13, 2020	SELL	$49.46 - $64.78 $4.76 Million - $6.24 Million	-96,293 Reduced 82.65%	20,212 $1.22 Million
Q4 2019 Feb 10, 2020	BUY	$49.86 - $58.26 $4.26 Million - $4.98 Million	85,430 Added 274.92%	116,505 $6.74 Million
Q3 2019 Nov 14, 2019	BUY	$47.54 - $53.43 $1.45 Million - $1.63 Million	30,574 Added 6102.59%	31,075 $1.61 Million
Q2 2019 Aug 14, 2019	SELL	$46.79 - $52.47 $729,830 - $818,427	-15,598 Reduced 96.89%	501 $25,000
Q1 2019 May 15, 2019	SELL	$46.36 - $52.63 $2.34 Million - $2.66 Million	-50,559 Reduced 75.85%	16,099 $842,000
Q4 2018 Feb 14, 2019	SELL	$41.54 - $47.25 $1.86 Million - $2.11 Million	-44,716 Reduced 40.15%	66,658 $3.07 Million
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $2.49 Million - $2.72 Million	-53,164 Reduced 32.31%	111,374 $5.25 Million
Q2 2018 Aug 14, 2018	BUY	$44.29 - $50.42 $5.84 Million - $6.65 Million	131,830 Added 403.05%	164,538 $7.59 Million
Q1 2018 May 15, 2018	SELL	$48.49 - $58.14 $1.59 Million - $1.91 Million	-32,778 Reduced 50.05%	32,708 $1.61 Million
Q4 2017 Feb 14, 2018	SELL	$47.53 - $53.73 $18,821 - $21,277	-396 Reduced 0.6%	65,486 $3.52 Million
Q3 2017 Nov 14, 2017	BUY	$41.15 - $49.22 $2.71 Million - $3.24 Million	65,882	65,882 $3.17 Million

Others Institutions Holding NVO

# of Institutions

1,957

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account